Biologics Safety Testing Market to Receive Favors from the Biopharmaceutical Sector
Market Overview:
The biopharmaceutical
industry is rapidly increasing as the global need for drugs based on life
science related products are increasing. Biopharmaceutical products, that
include drugs and vaccines, can carry contaminants. In the longer run, if not
handled carefully, these products can trouble patients. But the rising demand
has also set manufacturers on a track where they are now focusing more on the
manufacturing process. This process includes improved productivity, cost
efficiency, and deviations. But along with it comes safety testing measures.
These measures are of utmost importance as only they can ensure clearance from
governments for a widespread market. MRFR report on the same market includes
several aspects such as segmentation, competitive scenario, and factors that
can influence the market in performing better.
Market
Research Future (MRFR) in their latest report of the Biologics
Safety Testing Market revealed that the market can achieve 13.6% CAGR
during the forecast period (2018-2023). The biologics safety testing market can
scale far better market valuation than its previous USD 2.79 billion by the end
of 2023.
Increasing
regulations introduced by governments to create safer drugs are one of the
major factors that can thrust the biologics safety testing market forward. As a
square impact, this is forcing the biopharmaceutical companies to introduce latest technologies in their
manufacturing sector. This is also creating more space for the biologics safety
testing market expansion.
Competitive Landscape:
Notable
contributors of the global biologics safety testing market are Charles River Laboratories, Lonza Group
Ltd., Sartorius AG, Merck KGaA, Thermo Fisher Scientific Inc, SGS S.A., Wuxi
Apptec, Avance Biosciences Inc., Cytovance Biologics, Inc., and Eurofins
Scientific.
In
2018, Sartorius Stedim Biotech launched FlexAct BT that can detect any possible
leak in the Flexboy 2D bags that could take place during handling of it or
transportation. It does it by using ASTM F2095-01 pressure decay test to
maintain the safety standard of the bags.
Segmentation:
·
The
global biologics safety testing market, as per the reports of MRFR, has been
segmented into the product, test type,
and application.
·
Product-wise,
the biologics safety testing market can be segmented into kits and reagents,
services, and instruments. The kits and reagents segment has the maximum
market penetration as of 2017. The instruments segment is expected to
experience an uptick in the coming years.
·
Based
on the test type, the biologics safety testing market includes sterility tests,
bioburden tests, cell line authentication, and
characterization tests, endotoxin tests, adventitious agent detection tests, residual
host contamination detection tests, and others. The endotoxin test segment is
garnering accolades from biopharmaceuticals. The bioburden tests segment is
also deemed to prosper in the coming years.
·
Application-wise,
the biologics safety testing market includes cellular and gene therapy, vaccine
and therapeutics development, tissue & tissue-related products testing, blood
and blood-related products testing, and stem cell research.
Regional Analysis:
MRFR,
regionally, segments the global biologics safety testing market by the
Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The
Americas is leading the market from the front and is gaining substantial market
revenue. All credit goes to the U.S. The robust infrastructure in the
healthcare sector and research industry and their interconnected workflow are
things boosting the regional market further ahead. In addition, the presence of
FDA in the region has strict control over the quality which is making sure that
the products that come out are of the highest quality.
Europe
has the second biggest market and it can rely mostly on the investment made by
governments to promote safety of the product launched and innovations to steer
clear of any danger. The APAC market has several well-performing nations such
as China, Japan, Republic of Korea, India, and Australia, investing
substantially in enriching the quality of
such drugs. The region is deemed to be the fastest growing one due to the
revamped pharmaceutical and biotech industries.
Comments
Post a Comment